Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Supernus Pharmaceuticals, Inc. (SUPN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
32.16-0.65 (-1.98%)
At close: 04:00PM EDT
32.16 0.00 (0.00%)
After hours: 04:28PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Short-term KST

Short-term KST

Previous Close32.81
Open32.00
Bid26.00 x 1000
Ask35.56 x 900
Day's Range30.55 - 32.99
52 Week Range23.15 - 34.50
Volume652,235
Avg. Volume374,441
Market Cap1.72B
Beta (5Y Monthly)1.05
PE Ratio (TTM)25.32
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-23% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for SUPN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Supernus Pharmaceuticals, Inc.
    SUPN: Lowering target price to $29.00SUPERNUS PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $29.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
    Rating
    Fair Value
    Economic Moat
    last monthArgus Research
View more
  • GlobeNewswire

    Supernus Announces Second Quarter 2022 Financial Results

    Second quarter 2022 total revenues of $170.1 million, a 20% increase compared to second quarter 2021Second quarter 2022 GAAP operating earnings of $11.3 million; second quarter 2022 non-GAAP operating earnings of $37.6 millionQelbree® continued its growth trajectory, with 62,938 prescriptions in second quarter 2022, a 33% increase compared to first quarter 2022Second quarter 2022 Qelbree net product sales of $11.1 million increased 34% compared to first quarter of 2022; First six months 2022 Qel

  • GlobeNewswire

    Supernus Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on August 4, 2022

    ROCKVILLE, Md., July 25, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the second quarter of 2022 after the market closes on Thursday, August 4, 2022. Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conferenc

  • GlobeNewswire

    Supernus to Participate in the Jefferies Healthcare Conference

    ROCKVILLE, Md., June 02, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will present at the Jefferies Healthcare Conference on Thursday, June 9, 2022, at 10:30 a.m. ET. Investors interested in arranging a meeting with company management should contact th

Advertisement
Advertisement